YM-359445
an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor with highly potent antitumor activity against established tumors; structure in first source
Also Known As:
(3Z)-3-(6-((4-methylpiperazin-1-yl)methyl)quinolin-2(1H)-ylidene)-2-oxoindoline-6-carbaldehyde-O-(1,3-thiazol-4-ylmethyl)oxime mono-L-tartrate
Networked: 1
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Amino, Nobuaki:
1 article
(03/2006)
|
2. | Hisamichi, Hiroyuki:
1 article
(03/2006)
|
3. | Ideyama, Yukitaka:
1 article
(03/2006)
|
4. | Kudoh, Masafumi:
1 article
(03/2006)
|
5. | Kuromitsu, Sadao:
1 article
(03/2006)
|
6. | Matsuhisa, Akira:
1 article
(03/2006)
|
7. | Samizu, Kiyohiro:
1 article
(03/2006)
|
8. | Shibasaki, Masayuki:
1 article
(03/2006)
|
9. | Shirasuna, Kenna:
1 article
(03/2006)
|
10. | Tajinda, Katsuinori:
1 article
(03/2006)
|
Related Diseases
1. | Neoplasms (Cancer)
03/01/2006
- " In mice bearing various established tumors, including paclitaxel-resistant tumors, once daily oral administration of YM-359445 at doses of 0.5 to 4 mg/kg not only inhibited tumor growth but also reduced its vasculature. " 03/01/2006
- " YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors." 03/01/2006
- " Moreover, in human lung cancer A549 xenografts, YM-359445 markedly regressed the tumors (73%) at a dose of 4 mg/kg, whereas gefitinib caused no regression even at 100 mg/kg. Our results show that YM-359445 is more potent than orally bioavailable VEGFR2 tyrosine kinase inhibitors, which leads to great expectations for clinical applicability." 03/01/2006
- " The antitumor activity of YM-359445 was also tested in nude mice bearing various established tumors and compared with other VEGFR2 tyrosine kinase inhibitors (ZD6474, CP-547632, CGP79787, SU11248, and AZD2171), a cytotoxic agent (paclitaxel), and an epidermal growth factor receptor tyrosine kinase inhibitor (gefitinib). "
|
2. | Lung Neoplasms (Lung Cancer)
|
|
Related Drugs and Biologics
Related Therapies and Procedures